Nordea Investment Management AB Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Nordea Investment Management AB raised its stake in Johnson & Johnson (NYSE:JNJ) by 13.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,424,675 shares of the company’s stock after purchasing an additional 775,490 shares during the quarter. Johnson & Johnson accounts for 1.0% of Nordea Investment Management AB’s investment portfolio, making the stock its 13th biggest holding. Nordea Investment Management AB owned about 0.27% of Johnson & Johnson worth $926,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the company. Vinva Investment Management Ltd grew its position in shares of Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after purchasing an additional 7,110 shares during the period. Financial Counselors Inc. boosted its position in shares of Johnson & Johnson by 5.3% in the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock worth $29,996,000 after buying an additional 9,309 shares during the period. Meridian Investment Counsel Inc. boosted its stake in shares of Johnson & Johnson by 19.6% in the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after purchasing an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after acquiring an additional 102,502 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth approximately $69,859,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Morgan Stanley lifted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Bank of America restated a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 10th. Citigroup dropped their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Guggenheim lifted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Finally, Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $174.71.

Johnson & Johnson Stock Up 0.1 %

JNJ stock opened at $144.19 on Monday. Johnson & Johnson has a fifty-two week low of $142.75 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s fifty day moving average price is $151.40 and its two-hundred day moving average price is $156.28. The stock has a market capitalization of $347.16 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the company earned $2.66 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.44%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.